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evidence of sequestration 
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metabolites by extracellular 
vesicles of Fasciola hepatica
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fascioliasis is a neglected zoonotic disease that infects humans and ruminant species worldwide. 
in the absence of vaccines, control of fascioliasis is primarily via anthelminthic treatment with 
triclabendazole (TCBZ). Parasitic flatworms, including Fasciola hepatica, are active secretors of 
extracellular vesicles (eVs), but research has not been undertaken investigating eV anthelmintic 
sequestration. Adult F. hepatica were cultured in lethal and sub-lethal doses of tcBZ and its active 
metabolites, in order to collect eVs and evaluate their morphological characteristics, production and 
anthelmintic metabolite content. transmission electron microscopy demonstrated that F. hepatica 
exposed to tcBZ and its metabolites produced eVs of similar morphology, compared to non-tcBZ 
exposed controls, even though tcBZ dose and/or tcBZ metabolite led to measurable structural 
changes in the treated F. hepatica tegument. qnano particle analysis revealed that F. hepatica 
exposed to TCBZ and its metabolites produced at least five times greater EV concentrations than non-
TCBZ controls. A combined mass spectrometry and qNano particle analysis confirmed the presence of 
tcBZ and the tcBZ–sulphoxide metabolite in anthelmintic exposed eVs, but limited tcBZ sulphone 
was detectable. this data suggests that eVs released from adult F. hepatica have a biological role in 
the sequestration of tcBZ and additional toxic xenobiotic metabolites.
Fascioliasis is a neglected tropical disease which infects humans and ruminant species  globally1,2. Millions of 
people are at risk of this zoonotic disease, with at least 2.4 million people currently infected with fascioliasis in 
over seventy  countries3. Worldwide, the disease costs the livestock industry €2.5 billion annually, mainly due 
to significantly impacting upon animal health and food  security4. Fascioliasis is controlled by anthelmintic 
treatment, due to the absence of a commercial vaccine. Triclabendazole (TCBZ) is the anthelminthic treatment 
primarily used, due to its efficiency against adult and juvenile infections. Heavy reliance upon TCBZ in the past 
20 years for treating ruminant species and more recently humans, has led to TCBZ resistance, putting treatment 
strategies at  risk5.
TCBZ (6-chloro-5(2-3 dichlorophenoxy)-2-methyl thio-benzimidazole) is a halogenated benzimidazole 
thiol derivative that is distinguished from other benzimidazoles by a chlorinated benzene ring and the absence 
of a carbamate  moiety6. Following administration, TCBZ is metabolised in the host liver by sulphoxidation or 
hydroxylation into TCBZ sulphoxide (TCBZ–SO), TCBZ sulphone (TCBZ–SO2), hydroxy-TCBZ (TCBZ-OH), 
hydroxy-TCBZ–SO (TCBZ–SO-OH) or hydroxy-TCBZ–SO2 (TCBZ–SO2-OH). TCBZ–SO is reported as the 
most active metabolite, followed by TCBZ–SO2 and TCBZ, where hydroxylated metabolites are less  active7,8. The 
TCBZ sulphoxidation metabolism pathway primarily involves the flavin-monooxygenase system, although flavin-
monooxygenase and cytochrome P450 enzymatic systems are similarly involved in sulphonation of TCBZ–SO 
to TCBZ–SO28,9. In the host, the timing of peak metabolite plasma levels are known to vary dependent on 
metabolite, TCBZ–SO 18–24 h, TCBZ–SO2 36–48 h, TCBZ–OH 8 h, TCBZ–SO-OH 21 h and TCBZ–SO2-OH 
36 h. However, TCBZ–SO2 has been detected in plasma up to 5 days post-treatment7. TCBZ metabolites strongly 
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bind to plasma proteins, especially albumin, extending their activity in the host. Alternatively, TCBZ metabolites 
concentrate in the bile  ducts7. It has been demonstrated that sulpho-reduction and oxidation can be performed 
by rumen  microbes7,8. This suggests that gradual TCBZ release from plasma binding and rumen microflora 
metabolism prolongs exposure in the parasite host environment.
The primary mode for TCBZ metabolite toxicity towards Fasciola hepatica is inconclusive since TCBZ metab-
olites interact with many biological systems and exert cascading effects which have not all been  explored5. How-
ever, as TCBZ has similar biochemistry to benzimidazoles, which bind to the colchicine binding site on β-tubulin 
molecule receptors, the most expected mode of action involves disruption of microtubule-based processes. In F. 
hepatica, this has been supported by tegumental morphological studies where the adult or juvenile tegument has 
become synthetically inactive, disrupted and even autophagic when exposed to TCBZ, TCBZ–SO or TCBZ–SO2 
alongside colchicine microtubule inhibitors and tubulozole microtubule inhibitors as positive  controls9–12. In 
addition, loss of tubulin immunoreactivity in the tegumental syncytium, egg formation disruption and ovary, 
testes and vitelline cell apoptosis has been demonstrated, further supporting that TCBZ disrupts microtubule-
based processes in F. hepatica12–15. Uncertainty upon the TCBZ primary mode of action being disruption of 
microtubule-based processes, is in part due to the unknown binding site of TCBZ and its  metabolites5,6,11. Bio-
logical mechanisms such as the uncoupling of oxidative  phosphorylation16, the inhibition of protein  synthesis17 
and the stimulation of glucose derived acetate and  propionate18 have alternatively been investigated as likely 
TCBZ modes of action upon F. hepatica.
TCBZ metabolites enter F. hepatica via oral ingestion or trans-tegumental diffusion; the latter of which is 
dependent upon the diffusion surface area, TCBZ concentration gradient, environmental acidity and TCBZ 
 lipophilicity19,20. Alongside TCBZ, the metabolites TCBZ–SO and TCBZ–SO2 have been recovered from F. 
hepatica within 15 min of in vitro incubation, demonstrating rapid diffusion of TCBZ into F. hepatica20.
In F. hepatica, subpopulations of extracellular vesicles (EVs), determined by size and cargo content, have been 
found to be released from gastrodermal cells and tegumental  cells21,22. EVs are heterogeneous spherical struc-
tures on a nanometre scale, that are limited by a lipid bilayer and contain cytoplasmic  components23. To clarify, 
EVs is a collective term covering various subtypes of cell-released membranous structures called exosomes, 
microvesicles, microparticles, ectosomes, apoptotic bodies and many other  names24. To the best of the authors 
knowledge, only one study has been previously undertaken to investigate anti-parasitic drug exposure and 
parasite EV  production25. However, in non-parasitic research, the role of EVs during drug exposure is an area 
of intensive research specifically in the cancer and bacteriology fields. EVs have been observed to incorporate 
anti-cancer drugs, remove anti-cancer drugs from cancer cells and mediate cell acquired drug  resistance26. EVs 
have otherwise been investigated during drug exposure using gram negative and gram-positive bacteria  cells27–29. 
The primary reliance upon TCBZ to treat humans and livestock against fascioliasis, where resistance is prevalent, 
indicates the necessity of further TCBZ pharmacology research upon F. hepatica.
This novel study has discovered that F. hepatica exposed to TCBZ and its metabolites produced at least five 
times greater EV concentrations compared to treatment controls. In addition, TCBZ and its metabolites were 
observed in samples where F. hepatica was exposed to TCBZ and TCBZ–SO, although little was identified in 
samples where F. hepatica was exposed to TCBZ–SO2. Therefore, these results suggest that EVs are utilised to 
remove key TCBZ metabolites from the parasite’s microenvironment, to sustain F. hepatica survival.
Methods
fasciola hepatica culture and eV collection. Adult F. hepatica in vitro culture was revised from Mor-
phew et al.30. Adult F. hepatica (n = 420) were retrieved from naturally infected ovine livers immediately post-
slaughter from a local abattoir in mid Wales, U.K, during two visits. Immediately after collection, F. hepatica 
were thoroughly washed in phosphate buffered saline (PBS), pH 7.4, at 37 °C to remove host material. Replicates 
of ten adult similar sized matched F. hepatica were then cultured in 30  ml (3  ml/F. hepatica) culture media 
(Dulbecco’s modified Eagle’s medium (DMEM) (w/o  NaHPO3 and  PO4) plus 2.2 mM Ca  (C2H3O2), 2.7 mM 
 MgSO4, 61.1  mM glucose, 1  μM serotonin, 5  μg/ml gentamycin, 15  mM  N-2-hydroxyethylpiperazine-N′-2-
ethanesulfonic acid (HEPES), pH 7.4) in a falcon tube (Fisher Scientific) at 37 °C for 4 h, including transport 
to the laboratory, to establish a F. hepatica biological baseline (baseline controls). For control samples, 30 ml 
culture media in a falcon tube was similarly incubated at 37 °C for 4 h. Identical experimental procedures were 
undertaken after each abattoir visit.
Following initial culture, media was replaced and supplemented with either TCBZ (Sigma), TCBZ–SO 
(Sigma) or TCBZ–SO2 (Sigma) at 50 μg/ml (lethal dose) or 15 μg/ml (sub-lethal dose) in dimethyl sulfoxide 
(DMSO) (Sigma) (final conc. 0.1%, v/v) (anthelmintic exposure samples)31. Combining experiments undertaken 
after each abattoir visit, in total 60 F. hepatica were used for each TCBZ metabolite and concentration treat-
ment, which were separated into six falcon tubes (ten F. hepatica per falcon tube) (n = 6). Therefore, in total for 
anthelmintic treatment samples, 360 F. hepatica were used. All samples were incubated at 37 °C for 5 h, before 
F. hepatica were either snap frozen in liquid nitrogen or stored in ethanol for transmission electron microscopy 
analysis. Culture media was frozen and stored at − 80 °C until further use.
Three control groups were used in the study: treatment control, anthelmintic control and EV control. After ini-
tial culture, combining experiments undertaken after each abattoir visit, in total; the treatment controls included 
60 F. hepatica separated into six falcon tubes (ten F. hepatica per falcon tube) containing 30 ml culture media and 
DMSO (final conc. 0.1%, v/v) (n = 6); the EV controls included three falcon tubes containing 30 ml culture media, 
DMSO (final conc. 0.1%, v/v) and size exclusion chromatography (SEC) purified EVs previously derived from ten 
F. hepatica (the falcon tubes did not contain F. hepatica) (n = 3); the anthelmintic controls included three falcon 
tubes either containing TCBZ (n = 3), TCBZ–SO (n = 3) or TCBZ–SO2 (n = 3) at 50 μg/ml (lethal dose) in 30 ml 
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culture media and DMSO (final conc. 0.1%, v/v) (the falcon tubes did not contain F. hepatica or EVs). All control 
samples were incubated at 37 °C for 5 h, before the media was frozen and stored at − 80 °C until further use.
The viability of F. hepatica were scored with reference to Morphew et al.30 when collected at the abattoir 
(zero hour), after pre-incubation washing (cumulative 1 h), after 4 h baseline in vitro maintenance (cumulative 
5 h) and after 5 h TCBZ/SO/SO2 exposure in vitro maintenance (cumulative 10 h) (supplementary data S1). 
F. hepatica were classed as viable if they had a score > 1, a score of 1 deemed reduced viability and a score of 0 
denoted non-viable F. hepatica.
EV purification using size exclusion chromatography. Fasciola hepatica EV purification was fol-
lowed from Davis et al.32. Briefly, culture media was centrifuged at 300×g for 10 min at 4 °C and then at 700×g 
for 30 min at 4 °C, removing any large particulates. The samples were then concentrated using 10 KDa MWCO 
Amicon ultra-15 centrifugal filter units (Merck Millipore), following the manufacturer’s guidelines. Briefly, the 
samples were centrifuged at 4000×g for 20 min at 4 °C, until approximately 500 µl of samples were retained in the 
filter. The samples were passed through qEVoriginal SEC columns (IZON science), utilising the manufacturer’s 
optimised protocol. Briefly, the column was rinsed with 10 ml of filtered (0.2 μm, syringe filter, Life Sciences) 
PBS. The samples were then added to the SEC column and the first 2.5 ml of flow through was discarded. The 
next 2.5 ml of flow through, containing EVs, was collected and stored at − 80 °C for further analysis.
transmission electron microscopy (teM). Fasciola hepatica specimens from in vitro culture, were fixed 
in 2.5% v/v glutaraldehyde in 0.1 M sodium cacodylate (Agar Scientific), pH 7.2, overnight at 4 °C. Samples were 
then washed twice in wash buffer (0.1 M sodium cacodylate, pH 7.2) and then placed in wash buffer containing 
1% w/v osmium tetroxide solution (Agar Scientific) for 1 h. Samples were drained and two further buffer washes 
containing sodium cacodylate only were undertaken. Samples were then placed in an ultra-pure water bath and 
dehydrated in a series of ethanol dilutions (30%, 50%, 70%, 95% and 100% v/v) for 1 h. Samples were embedded 
in resin, whereby infiltration was achieved using ethanol mixtures (2:1, 1:1 and 1:2) and LR white (hard grade) 
resin (London Resin Company Ltd). Samples were transferred to gelatine or polyethylene moulds and poly-
merised overnight at 60 °C. Sections (1–2 μm) were cut and dried onto glass slides, before staining with azur II 
(Sigma) or methylene blue (Sigma) for 2 min. Ultrathin (60–80 nm) sections were then cut using Reichert-Jung 
ultracut E ultramicrotome with a diatome ultra 45° diamond knife and collected on nickel slot grids (GS2X0.5 
3.05 mm diameter gilder grids, Grantham, UK) float-coated with butvar B98 polymer films (Agar Scientific). All 
sections were double-stained with a 4:1 dilution of 5% w/v uranyl acetate (Agar Scientific) in iso-propyl alcohol 
(Sigma) and Reynold’s lead citrate (6.65 g of lead nitrate mixed with 8.80 g of tri-sodium citrate in 100 ml dis-
tilled water) (TAAB Laboratories Equipment Ltd, Aldermaston, UK) for tegument TEM imaging (Jeol JEM1010 
microscope at 60 kV).
Fasciola hepatica EV TEM methodology was followed from Davis et al.32. Briefly, EV samples were fixed onto 
formvar/carbon coated copper grids (Agar Scientific) by adding 10 µl sample to the grid for 45 min on ice. Grids 
were then placed on the viscous of 4% v/v uranyl acetate for 5 min on ice. Grids were stored at room temperature 
for at least 24 h before being imaged using the TEM (Jeol JEM1010 microscope at 60 kV).
Images were photographed on Carestream 4489 electron microscope film (Agar Scientific). Film images were 
developed (Kodak D-19 developer) for 4 min at 20 °C, before being fixed, washed and dried according to the 
manufacturer’s instructions. The resulting negatives were scanned (Epson Perfection V800 film scanner) and 
converted to positive images. The size of 100 EVs from anthelmintic exposure samples and treatment controls 
were measured (nm) using ImageJ (https ://image j.nih.gov/ij/) as described  previously32.
Particle size and concentration quantification by qNano particle analysis. EV samples or cali-
bration particles (CPC200, 1:1000 filtered (0.2 μm, Life Sciences) PBS dilution, Izon science) were placed in the 
Nanopore (NP200, Izon science) on the qNano device (Izon science). All samples and calibration particles were 
measured at 47 mm nanopore stretch with a voltage of 100 nA at pressure level 7 mbar. Short current pulses 
detected the particles. Sample analysis was conducted using qNano particulate analysis (Izon, version 3.2).
eV sample preparation, mass spectrometry and tcBZ/So/So2 identification. One millilitre of 
all TCBZ/SO/SO2 exposure EV samples and control samples was ultra-centrifuged (S55-S rotor, Sorval MX120 
centrifuge, Thermo scientific) at 100,000×g for 30 min at 4  °C and the PBS supernatant was removed. Next, 
500 μl Absolute ethanol (VWR) was added to the pellet, before sonicating for 30 s and resting on ice for 30 s. 
This was repeated twice to lyse EVs. Ethanol was then evaporated, using a vacuum concentrator (Maxi dry plus, 
Heto) and 100 μl 70% methanol (VWR) was added to the pellet. The samples were vortexed for 30 min, before 
centrifuging at 10,000×g for 2 min. TCBZ/SO/SO2 metabolite standard samples were prepared using concentra-
tions: 100 ng/ml, 75 ng/ml, 50 ng/ml, 25 ng/ml, 10 ng/ml, 5 ng/ml and 2.5 ng/ml in 100 μl 70% methanol and 
were vortexed and centrifuged at 10,000×g for 2 min. 20 μl of all sample supernatants and standard supernatants 
were then prepared in sampling vials (Thermo scientific) and randomly ordered for mass spectrometry.
Metabolites were evaluated as described in Akpanika et al.33 using reverse-phase high performance liquid 
chromatography with online photodiode array detection and electrospray ionisation-ion trap tandem mass 
spectrometry (HPLC–PDA-ESI/MSn). Structural elucidation was completed on a Thermo Finnigan liquid chro-
matography mass spectrometry system (Thermo Electron Corporation) including a Finnigan photo diode array 
plus detector, a Finnigan linear trap quadrupole with electrospray ionization source, and a C18 Nova-Pak column 
(3.9 × 100 mm, particle size 4 μm, Waters) where the column oven temperature was maintained at 30 °C. The 
photodiode array detection scan range was 240–400 nm, with 10 μl injection volume. The mobile phase included 
water with 0.1% v/v formic acid (solvent A) and methanol with 0.1% v/v formic acid (solvent B). The column was 
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equilibrated using 95% v/v solvent A with a 1 ml min−1 flow rate, where 10% entered the mass spectrometer, and 
solvent B percentage increased linearly to 65% v/v over 60 min. Mass spectrometry parameters were: sheath gas 
30, auxiliary gas 15, sweep gas zero (all arbitrary units), spray voltage − 4.0 kV in negative and 4.8 kV in positive 
ionisation mode, capillary temperature 320 °C, capillary voltage − 1.0 V and 45.0 V respectively, tube lens voltage 
− 68 V and 110 V respectively, and normalised collision energy 35%.
Mass spectrometry spectrum peaks for anthelmintics: TCBZ, TCBZ–SO, TCBZ–SO2, TCBZ-OH, 
TCBZ–SO-OH and TCBZ–SO2-OH in all TCBZ/SO/SO2 exposure samples, TCBZ metabolite standard sam-
ples and control samples were manually identified by molecular weight and scan time using Xcalibur software 
(Version 3.0) (Thermo scientific) (supplementary data S2). The spectrum peak area of all samples was recorded. 
TCBZ/SO/SO2 metabolite standard sample spectrum peak areas were used to create standard curves for TCBZ/
SO/SO2 metabolite quantification (ng) of TCBZ/SO/SO2 exposure samples and control samples. The amount of 
TCBZ/SO/SO2 metabolite found in EVs (pg/particle9) was determined by spectrum peak area quantification (ng) 
and qNano particle analysis sample concentration (particle/ml) in all TCBZ/SO/SO2 exposure samples and con-
trol samples. Any background metabolite concentration found in TCBZ/SO/SO2 control samples, was deducted 
from TCBZ/SO/SO2 exposure samples and other control samples. Sample spectrum peak areas below 1000 
were disregarded from the results, as this data could not be confidently defined from spectra background noise.
Statistical analysis. The Shapiro–Wilk test and quantile–quantile plots were used to identify data normal-
ity (p > 0.05). Kruskal–Wallis one-way analysis of variance with post hoc Nemenyi test was used to analyse EV 
diameter measurements using TEM and ImageJ analysis. The independent welch two samples T-test, a one-way 
or a two-way ANOVA with post-hoc Fisher’s least significant difference test was conducted to identify significant 
differences between TCBZ/SO/SO2 exposure samples and control samples using qNano particle analysis and 
mass spectrometry. One outlier from the treatment controls and lethal TCBZ–SO2 exposure sample was omitted 
in the particle diameter data. In addition, one sub-lethal and lethal TCBZ–SO exposure replicate was omitted 
prior to statistical analysis in Fig. 5, as the sample spectrum peak areas were below 1000.
Results
fasciola hepatica survival. All F. hepatica survived 10 h in vitro maintenance, where only 2% F. hepatica 
sub-lethal TCBZ/SO/SO2 and lethal TCBZ–SO exposure samples, 3% F. hepatica lethal TCBZ exposure samples, 
and 7% F. hepatica lethal TCBZ–SO2 exposure samples presented reduced viability (viability score of 1) (sup-
plementary data S1).
eV morphological characteristics comparison. TEM micrographs identified that lethal or sub-lethal 
TCBZ/SO/SO2 exposure samples had similar EV morphology, compared to treatment and EV control samples 
(Fig. 1). When using qNano particle analysis, particle diameter was similar between all TCBZ/SO/SO2 exposure 
samples and the treatment controls (TCBZ [15 μg/ml] = 160.4 nm ± 77.1 SD, TCBZ [50 μg/m] = 175.5 nm ± 74.2 
SD, TCBZ–SO [15 μg/ml] = 167.6 nm ± 83.5 SD, TCBZ–SO2 [15 μg/ml] = 167.6 nm ± 71.5 SD, TCBZ–SO2 [50 μg/
ml] = 177.2 nm ± 78.4 SD, treatment control = 173.1 nm ± 81.3 SD), with the exception of the lethal TCBZ–SO 
exposure samples (TCBZ–SO [50 μg/ml] = 147.9 nm ± 67.4 SD), which had significantly smaller particle diam-
eter size compared to the treatment controls  (F(6,34) = 2.7, p = 0.03) (Fig. 2). Two way ANOVA identified that there 
was no significance between particle diameter and lethal or sub-lethal anthelmintic dose  (F(1,31) = 0.0, p = 0.94), as 
well as TCBZ metabolite  (F(2,31) = 2.3, p = 0.11).
Kruskal–Wallis one-way analysis of variance showed there was a significant statistical difference (χ2(6) = 56.96, 
p < 0.001) between treatment and control sample EV diameter using TEM image analysis, where lethal TCBZ 
(TCBZ [50 μg/m] = 53.2 nm ± 44.1 SD, p = 0.01) and TCBZ–SO (TCBZ–SO [50 μg/m] = 48.8 nm ± 29.9 SD, 
p = 0.009) exposure samples had significantly smaller diameter size compared to the treatment controls (treatment 
control = 62.6 nm ± 32.4 SD). In addition, sub-lethal TCBZ exposure samples (TCBZ [15 μg/ml] = 74.3 nm ± 33.8 
SD, p < 0.001) were observed to have a significantly higher diameter size compared to anthelmintic exposure 
samples (TCBZ–SO [15 μg/ml] = 61.9 nm ± 51.2 SD, TCBZ–SO2 [15 μg/ml] = 52.6 nm ± 29.2 SD, TCBZ–SO2 
[50 μg/ml] = 51.6 nm ± 31.3 SD).
eV release comparison. TEM micrographs demonstrated that EV release was similar in all TCBZ/SO/SO 
exposure samples, compared to the treatment controls (Fig. 3). Although, the tegument showed clear structural 
changes where disorganised tissues and small spaces in the tissue were noted following anthelmintic exposure, 
especially when exposed to TCBZ–SO, compared to the treatment controls.
qNano particle analysis demonstrated that TCBZ/SO/SO2 exposure samples had at least five times greater 
particle concentration than the treatment controls (Fig. 4). Specifically, there was a significantly greater particle 
concentration between sub-lethal TCBZ dose, lethal and sub-lethal TCBZ–SO, lethal and sub-lethal TCBZ–SO2 
dose exposure compared to the treatment controls  (F(6,34) = 2.7, p = 0.03). Two way ANOVA identified that there 
was no significance between particle concentration and lethal or sub-lethal anthelmintic dose  (F(1,32) = 2.0, 
p = 0.17), as well as anthelmintic metabolite  (F(2,32) = 0.7, p = 0.53).
eV tcBZ/So/So2 uptake comparison. No anthelmintic metabolites were identified in the baseline con-
trols and treatment controls, confiming that there was no cross-contamination of anthelmintic, while undertak-
ing methodology protocols (supplementary data S2). Anthelmintic metabolites were observed in two TCBZ–SO 
and TCBZ–SO2 anthelmintic control samples, so metabolite concentations were averaged and deducted from 
TCBZSO/SO2 EV controls and TCBZSO/SO2 exposure sample results, to remove the maximum TCBZSO/SO2 
concentration background which was possibly not uptaken by EVs but still remained in samples. One sub-lethal 
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Figure 1.  TEM micrographs demonstrating F. hepatica EVs from the treatment control (n = 3) and a SEC 
purified EVs (EV control) dosed with lethal (50 μg/ml) TCBZ, TCBZ–SO or TCBZ–SO2 in DMSO (0.1%, v/v) 
from top to bottom, respectively (n = 3), b EVs from adults F. hepatica exposed to sub-lethal (15 μg/ml) doses of 
TCBZ, TCBZ–SO or TCBZ–SO2 in DMSO (0.1%, v/v) from top to bottom, respectively (n = 3) and c EVs from 
adults F. hepatica exposed to lethal (50 μg/ml) doses of TCBZ, TCBZ–SO or TCBZ–SO2 in DMSO (0.1%, v/v) 
from top to bottom, respectively (n = 3). Images were captured at 50× magnification.
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and lethal TCBZ–SO sample and one sub-lethal and lethal TCBZ–SO2 sample were observed to have a spectrum 
peak area below 1000, and thus were removed from the results, as samples could not be confidently defined from 
spectra background noise. Anthelmintic concentrations in EVs were observed in all TCBZ exposed samples 
and all TCBZ–SO exposed samples, other than one TCBZ–SO EV control replicate. TCBZ–SO2 concentrations 
were observed in only one replicate of TCBZ–SO2 EV control, one replicate of TCBZ–SO2 sub-lethal expo-
sure sample and two replicates of lethal TCBZ–SO2 exposure samples (Fig. 5). There was a significantly greater 
TCBZ concentration in EVs when F. hepatica was exposed to TCBZ (n = 6), in comparison to TCBZ–SO anthel-
mintic concentrations in EVs when F. hepatica were exposed to TCBZ–SO (n = 5)  (F(1,19) = 5.1, p = 0.04). There 
was no significance difference between anthelmintic dosage within TCBZ and TCBZ–SO exposure treatment 
 (F(1,19) = 2.7, p = 0.12).
TCBZ was identified in two TCBZ–SO EV controls, two lethal TCBZ–SO exposure replicates and one sub-
lethal TCBZ–SO exposure replicate. Otherwise, no other alternative anthelmintic metabolites were observed in 
controls and TCBZ/SO/SO2 exposure samples.
Discussion
Reliance upon TCBZ to treat humans and livestock against fascioliasis, where F. hepatica TCBZ resistance has 
been reported, indicates the urgency to advance TCBZ pharmacology research involving F. hepatica. Thus, 
given the characteristics of extensively documented cancer drug-human EV  interactions26, it seems logical to 
investigate the role of F. hepatica EVs following adult Fasciola hepatica exposure to TCBZ and its metabolites. 
This research has provided new insights upon how F. hepatica EVs are involved in F. hepatica survival during 
anthelmintic exposure, by investigating EV morphological characterisation, EV release and EV anthelmintic 
metabolite contents.
Fasciola hepatica cultured in lethal and sub-lethal doses of TCBZ/SO/SO2 had similar EV morphology to 
treatment control samples and F. hepatica EV morphology reported in previous  investigations32. EV diameter 
measurements using qNano particle analysis and TEM showed that lethal and sub-lethal doses of TCBZ/SO/SO2 
were similar sizes to treatment control EV samples, other than F. hepatica cultured in lethal TCBZ–SO which had 
significantly lower particle diameter size. TCBZ–SO is the most active TCBZ metabolite against F. hepatica, so it 
could be possible that the change in EV size, a reduction in this case, is due to metabolite  potency7,8. Addition-
ally, TEM EV diameter measurements identified that lethal TCBZ had significantly lower particle diameter size 
compared to treatment control samples and sub-lethal TCBZ exposure samples had significantly higher diam-
eter size compared to anthelmintic exposure samples. Not only were these significant results different between 
methodologies, but TEM EV diameters were smaller than qNano particle analysis measurements. Comparison 
between TEM EV diameter measurements and nanoparticle tracking analysis (NTA) similarly found that EVs 
were smaller using TEM methodology, which was suggested to be due to NTA EV aggregate  measurements34. 
Additionally, TEM fixing and staining methodology, which is not required for qNano particle analysis, leads to 
a characteristic central depression in EV  morphology35, which is likely to adversely affect EV size and shape. In 
this case, this outcome is unrelated to F. hepatica survival under the conditions and duration of the assays, as 
Figure 2.  Particle diameter (nm) of control (n = 6) or drug exposure samples with lethal (50 μg/ml) or sub-
lethal (15 μg/ml) doses of TCBZ/SO/SO2 (weighted mean ± weighted SD) (n = 6), where letters a and b represent 
significance (p < 0.05). One-way ANOVA and Fisher’s LSD identified significance (p < 0.05) between drug 
exposure samples and the treatment control (F(6,34) = 2.7, p = 0.03). Two way ANOVA identified no significance 
between particle diameter and lethal or sub-lethal drug dose  (F(2,1) = 0.1, p = 0.80), as well as drug metabolite 
 (F(2,1) = 2.8, p = 0.08). One outlier was removed from lethal TCBZ–SO2 drug dose (n = 5).
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lethal TCBZ–SO, lethal TCBZ and sub-lethal TCBZ anthelmintic exposure parasites had similar viability scores 
as sub-lethal TCBZ/SO/SO2 exposure parasites.
Comparable EV release from the tegument was identified when F. hepatica were exposed to lethal TCBZ/SO/
SO2, in comparison to the treatment controls. However, the tegument exhibited structural changes after TCBZ/
SO/SO2 exposure, especially when exposed to TCBZ–SO metabolite, compared to the treatment controls. Further 
detailed TEM images of F. hepatica tegumental syncytium after 24-h sub-lethal TCBZ/SO/SO2 exposure, identi-
fied swollen basal infolds and disorganised tissues with small spaces between intact  muscle9. Anthelmintic expo-
sure also caused reduced secretory bodies, swollen mitochondria and a lack of Golgi complexes in tegumental 
 tissue9. Severity of damage largely varied between TCBZ and the two  metabolites9, as noted in the current study.
Fasciola hepatica exposed to lethal and sub-lethal TCBZ/SO/SO2 had five-fold greater EV release, compared to 
the treatment controls. Specifically, there was a significantly greater particle concentration between all sub-lethal 
anthelmintic exposure samples and lethal TCBZ–SO and TCBZ–SO2 exposure samples, compared to the treat-
ment controls. In contrast, the only EV-drug parasite experiment previously undertaken, demonstrated a rapid 
inhibition of EV release when Brugia malayi and Dirofilaria immitis were cultured with ivermectin over a 24-h 
 period25. However, antibiotic treatments upon S. maltophilia and Escherichia coli cultures have led to increased 
outer membrane vesicle  release28,29. Furthermore, photodynamic treatment and chemotherapy increased levels 
of cancer cell circulating EVs several fold in a dose dependant  manner36, supporting the current study findings. 
Other investigations in the cancer field have observed chemotherapeutic treatments inhibiting EV release, temo-
zolomide and geldanamycin glioblastoma treatment decreased microvesicle release dose-dependently, attributing 
Figure 3.  TEM micrographs showing the tegument of F. hepatica anthelmintic exposure and treatment control 
samples where a DMSO (0.1%, v/v) only (treatment control) (n = 3), b TCBZ (50 μg/ml) in DMSO (0.1%, v/v) 
(n = 3), c TCBZ–SO (50 μg/ml) in DMSO (0.1%, v/v) (n = 3), or d) TCBZ–SO2 (50 μg/ml) in DMSO (0.1%, 
v/v) (n = 3). Images were taken at 15× magnification and arrows indicate tegument structural changes such as 
disorganised tissues and small spaces in the tissue at the apical plasma membrane (APM), and EV release (EV) 
following anthelmintic exposure, compared to the treatment control.
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to drug-induced cell  death37 and exosome concentration decreased two-fold in the urine of prostate cancer 
patients, following a 12-week treatment of androgen deprivation  therapy38.
Anthelmintic dose or metabolite did not affect particle concentration, when F. hepatica were exposed to 
lethal and sub-lethal TCBZ/SO/SO2. It could be possible that greater EV release is due to anthelmintic toxicity 
causing tissue disorganisation and spaces between muscles in the tegument syncytium, allowing uncontrolled 
stress-induced EV release. This proposal would explain why neither the anthelmintic dose used, nor the anthel-
mintic metabolite chosen, did not specifically influence F. hepatica EV release. Interestingly, hepatocellular 
carcinoma cell exosome secretion was increased by anticancer chemotherapeutics or via heat shock. In this 
Figure 4.  Particle concentration (particles/ml) of control (n = 5) or anthelmintic exposure (n = 6) with lethal 
(50 μg/ml) or sub-lethal (15 μg/ml) doses of TCBZ, TCBZ–SO or TCBZ–SO2 (mean + SD) where letters a and 
b represent significance (p < 0.05). One-way ANOVA and Fisher’s LSD test identified significance (p < 0.05) 
between drug exposure samples and the treatment control (F(6,34) = 2.7, p = 0.03). Two way ANOVA identified 
that there was no significance between particle diameter and lethal or sub-lethal drug dose (F(1,32) = 2.0, 
p = 0.17), as well as anthelmintic metabolite (F(2,32) = 0.7, p = 0.53). One outlier was removed from the control 
(n = 5).
Figure 5.  EV drug concentration (pg/particle9) in EV control (50 ug/ml) (n = 3) or drug exposure samples 
with lethal (50 μg/ml) or sub-lethal (15 μg/ml) doses of TCBZ (n = 6), TCBZ–SO (n = 5) or TCBZ–SO2 (n = 5) 
(mean ± SD). Two way ANOVA identified that there was no significance between lethal and sub-lethal EV 
anthelmintic concentration  (F(1,19) = 2.7, p = 0.12) between TCBZ and TCBZ–SO exposure treatments but there 
was a significantly greater TCBZ concentration in EVs (n = 6) in comparison to TCBZ–SO EV anthelmintic 
concentrations (n = 5)  (F(1,19) = 5.1, p = 0.04). One TCBZ–SO sub-lethal and lethal anthelmintic exposure 
replicate was omitted from statistical analysis, as sample spectrum peak areas were below 1000.
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instance, exosomes carried a greater amount of heat shock proteins when exposed to anticancer chemothera-
peutics, suggesting exosome release was stress-induced39.
TCBZ and TCBZ–SO concentrations were identified in EVs, where F. hepatica exposed to TCBZ had a signifi-
cantly higher TCBZ concentration in EVs, compared to TCBZ–SO. Limited TCBZ–SO2 was detected in EVs from 
F. hepatica exposed to TCBZ–SO2. EV chemotherapeutic uptake has been recognised in many cancer cell line 
EV  studies40–47. As anthelmintic dose did not affect anthelmintic concentration observed in EVs, it is suggested 
that anthelmintic EV uptake was mostly passive. TCBZ (log Pow = 5.3) is the most hydrophobic metabolite, so 
is more likely to be distributed in EVs than the other metabolites, while TCBZ–SO2 (log Pow = 3.4) is the least 
hydrophobic metabolite and is less likely to be distributed in EVs compared with other TCBZ metabolites, sup-
porting the current study findings. Similar results were discovered when shed vesicles were isolated from cancer 
cells which passively accumulated and retained doxorubicin dose-dependently. Thermodynamic binding interac-
tions were suggested to explain chemotherapeutic accumulation, and lipid complex formation was found to be 
involved in chemotherapeutic  retention48. A range of methods are used to purposely load treatments into EVs 
including incubation, where temperatures of 22–37 °C lead to chemotherapeutic EV uptake within a few  hours49. 
This indicates that the incubation period for experimental F. hepatica culture, and in vivo conditions, may be 
optimal for anthelmintic passive diffusion into EVs. However, the potential that TCBZ and its metabolites could 
be up taken by active processes by F. hepatica EVs should not be dismissed. Drug accumulation in cell membranes 
where EVs are produced has been reported to allow drug removal from cancer  cells44,48. In depth investigations 
on the EV uptake mechanism of anthelmintics, would be beneficial to improve fascioliasis control strategies.
Alternative TCBZ metabolites were noted in two TCBZ–SO EV controls, two lethal TCBZ–SO and one sub-
lethal TCBZ–SO replicates. Sulpho-reduction and oxidation has only been previously noted in sheep ruminal 
fluid under anaerobic  conditions8. Phase I detoxification of chemical stressors in adult parasitic helminths is 
dominated by reductive and hydrolytic-based metabolisms, where sulphoxidation occurs by enzymes in different 
cellular locations, and TCBZ–SO is oxidised to the less active TCBZ–SO250,51. Phase II studies have been focused 
on glutathione conjugation, with extensive investigations upon the role of glutathione transferase detoxifying 
reactive oxygen  intermediates50. Fatty acid binding proteins, in addition to their transport roles for fatty acids, 
sterols, lysophospholipids and nonpolar organic ions (e.g. haem and bile pigments), also sequester toxins such 
as reactive oxygen intermediates, so are considered to have evolved phase III detoxification  roles52. Interestingly, 
anthelmintic metabolising, sequestration and efflux pump proteins have been observed in the proteomic profile 
of F. hepatica EVs including aldo/keto reductases, amidase, phosphodiesterase, glutathione transferase, methyl 
transferase, ABC transporter transmembrane, P-glycoprotein and fatty acid binding  protein22,32,53,54 further sug-
gesting that EVs are organelles with specialised detoxification functions.
In summary, F. hepatica exposed to TCBZ and its metabolites produced at least five times greater EV con-
centrations than controls, albeit this may not be a pro-active and direct parasite detoxification strategy, but 
indirect via tegumental tissue disorganisation initiated by anthelmintic toxicity. However, the presence of active 
anthelmintic metabolites were measurable in EVs released from F. hepatica. Therefore, anthelmintic uptake by 
EVs is likely to reduce the availability of at least some active TCBZ compounds in the parasite’s microenviron-
ment, contributing towards F. hepatica survival. Additional investigation upon the retention of anthelmintics 
with in EVs and bespoke mechanisms of EVs to potentially remove or metabolise anthelmintics, would improve 
our understanding of the significance of our observations. Further research with defined isolates should now 
be undertaken to determine if there is a contribution provided by F. hepatica EVs towards TCBZ resistance 
mechanisms.
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